Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649
{{output}}
Background: We report efficacy and safety results from the CheckMate 649 trial after 5 years of follow-up. Patients and methods: Adults with pr... ...
